FundraiseBase by

Aeovian Pharmaceuticals

Raised $55M in a Series B round, announced 16 December 2025.

Round

Funds Phase 2 proof-of-concept study of AV078 in TSC-related epilepsy.

Amount: $55M
Stage: Series B
Announced: 16 December 2025
Lead: Luma Group
Other investors: CTI Life Sciences Fund, Foresite Capital, SymBiosis, TSC Alliance Endowment Fund
Use of funds: Funds Phase 2 proof-of-concept study of AV078 in TSC-related epilepsy.
Checked: Announced by the company

Company

Clinical-stage developer of selective mTORC1 inhibitors for epilepsy

Based in: United States
Sector: Health
Website: aeovian.com ↗

Sources and links

Sources: Aeovian Pharmaceuticals Raises $55 Million to Advance First-in-Class Selective mTORC1 Inhibitor for Tuberous S businesswire.com
Aeovian Pharmaceuticals Raises $55 Million to Advance First-in-Class Selective mTORC1 Inhibitor for Tuberous S news.google.com
Aeovian Pharmaceuticals Raises $55 Million to Advance First-in-Class Selective mTORC1 Inhibitor for Tuberous S alleywatch.com
Website: aeovian.com ↗

Just raised?

MediaBoost gets your round in front of the press, future hires and your next investors.

Announce your round with MediaBoost